aPROMISE™ (Automated Prostate Molecular Imaging Standardized Evaluation) is a deep learning application and FDA-cleared, CE-marked medical device software developed to bring consistency, efficiency, and standardization to the assessment of PSMA PET/CT scans for prostate cancer. The software, which functions as a PACS platform, uses deep learning technology to automate the segmentation of anatomical regions (like the liver and aorta) in low-dose CT images. It then detects, localizes, and quantifies potential pathological lesions in the PSMA PET/CT images, significantly reducing the laborious task of manual quantification and improving inter-reader reproducibility.
Key Capabilities:
- Quantitative Assessment: Generates quantitative total disease burden indices, such as the Quantitative PSMA Scan Index (PSI). These biomarkers support patient selection for treatment, including PSMA radioligand therapy (RLT), and automate the monitoring of response over time.
- Efficiency: The system is designed to create a comprehensive, quantitative report in an average of approximately three minutes, enhancing clinical workflow.
- Standardization: The platform supports standardized reporting, aligning with guidelines like E-PSMA.
- Viewer: Includes a multi-modal viewer with PET, CT, Fusion, and MIP views, enabling healthcare professionals to review and verify the automated analysis.
Target Users & Use Cases:
- Target Users: Nuclear Medicine Physicians, Radiologists, Oncologists, and Researchers.
- Use Cases: Prostate cancer staging and diagnosis, monitoring treatment response, assessing quantitative tumor burden, and clinical trial analysis.